Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10301471 | 1.00 | HPGD (0.50) | HPGDRAB9ANPC1DPP4DPP7 | |
| SCHEMBL3303393 | 1.00 | HPGD (0.50) | HPGDRAB9ANPC1DPP4DPP7 | |
| SCHEMBL367603 | 1.00 | HPGD (0.50) | HPGDRAB9ANPC1DPP4DPP7 | |
| SCHEMBL367911 | 1.00 | HPGD (0.50) | HPGDRAB9ANPC1DPP4DPP7 | |
| SCHEMBL368344 | 1.00 | HPGD (0.50) | HPGDRAB9ANPC1DPP4DPP7 | |
| SCHEMBL3299190 | 1.00 | HPGD (0.50) | HPGDRAB9ANPC1DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL296483 | 0.98 | HPGD (0.49) | HPGDRAB9ANPC1DPP4DPP7 | |
| SCHEMBL10305139 | 0.86 | HIF1A (0.41) | HPGDRAB9ADPP4DPP7DPP8 | |
| SCHEMBL10030138 | 0.84 | DPP4 (0.52) | DPP4DPP7DPP8DPP9ALDH1A1 | |
| SCHEMBL2696470 | 0.84 | DPP4 (0.52) | DPP4DPP7DPP8DPP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481407-B1 | Compounds for use in treating cognitive disorders | ALLERGAN INC (US) | 2018-09-26 | — | — | EP | claimed |
| US-20140296287-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2014-10-02 | — | — | US | claimed |
| US-20140179925-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2014-06-26 | — | — | US | claimed |
| EP-2481407-A1 | Compounds for use in treating cognitive disorders | Allergan, Inc. (US) | 2012-08-01 | — | — | EP | claimed |
| US-20100093793-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | claimed |
| EP-2131837-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| WO-2008109610-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| EP-2481407-A1 | Compounds for use in treating cognitive disorders | Allergan, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179925-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2C, GRIN2A | HPGD 472/4885RAB9A 1769/4885NPC1 623/4885 |
| US-20140296287-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2C, GRIN2A | HPGD 472/4885RAB9A 1769/4885NPC1 623/4885 |
| US-20100093793-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, AADAT, AANAT | HPGD 395/4885RAB9A 1759/4885NPC1 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.